QuANTUM-First: impact of co-mutations on quizartinib outcomes in FLT3-ITD+ AML

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses an analysis of the QuANTUM-First trial (NCT02668653) that assessed the impact of co-mutations on the benefit of quizartinib for patients with FLT3-ITD+ acute myeloid leukemia (AML). Dr Erba highlights that patients with NPM1 and DNMT3A mutations, but not those with MDS-related mutations, showed an improvement in overall survival and relapse-free survival with quizartinib, suggesting that quizartinib may overcome the negative prognostic impact of these co-mutations. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.